Table 2.

Baseline characteristics of the BETA trial by treatment group.

Time Point	Placebo Number of Patients with MHE/Number of Total Evaluated Patients and Percentage	Albumin Number of Patients with MHE/Number of Total Evaluated Patients and Percentage
Day 2–3	6/9 (66.6)	5/13(38.5)
Day 7	7/12(58.3)	4/17(23.5)
Day 30	4/10(40)	5/16(31.3)
Day 60	1/4(25)	5/14(35.7)
Day 90	6/12(50)	4/16(25)
Day 180	2/6(33.3)	3/13(7.7)

No significant differences were found at any time point. Abbreviations: minimal hepaticencephalopathy, MHE.